

Atlantic Pharmaceuticals, Inc. Announces Completion of Phase 1 NIH Grant for Sustained Release Injectable Analgesic

Atlanta, GA, April 2009 – Atlantic Pharmaceuticals, a specialty pharmaceutical company, today announced that it has completed a Phase 1 Small Business Innovative Research (SBIR) grant for a sustained release depot of buprenorphine indicated for sustained analgesia in post surgical animals. The grant was received through the National Institutes of Health via the National Institutes of Comparative Medicine.

Atlantic's proprietary injectable platform was developed in conjunction with the University of Tennessee and is an inexpensive, convenient and robust platform ready for advanced testing.

It is generally agreed that pain adversely impacts the welfare of animals. Pain can also confound the interpretation of experimental results if it is not controlled. Effective treatment of pain in laboratory animals is often a difficult task, especially if the pain medications are to be administered frequently, i.e. several times a day for several days. Hence, veterinarians often administer analgesics preemptively if they think that a procedure will induce pain in an animal. Management and treatment of pain can only be considered successful if the degree of pain does not prevent an animal from engaging in relatively normal activities, such as eating, sleeping, ambulating, grooming, and interacting with other members of its species or its care givers.

Anthony Soscia, President of Atlantic Pharmaceuticals said, "Research animals often undergo painful procedures which require around the clock administration of analgesia to comply with the strict U.S. guidelines for treatment. Unfortunately animals cannot tell you when they are in pain and an inexpensive sustained release analgesic would keep the animals from experiencing any unnecessary discomfort."

Mr. Soscia added, "We believe that we have exceeded our internal original milestones set for the proof of concept and look forward to pursuing this product to the next stage of development.

About Atlantic Pharmaceuticals

Atlantic Pharmaceuticals, Inc., is a privately held specialty pharmaceutical company dedicated to the discovery and development of innovative, late stage therapies for substance abuse and pain related conditions and diseases. Our products target therapeutic opportunities utilizing molecules shown to be safe and effective with formulations that are protected by intellectual property. We believe that our approach will lead to improved patient care, reduced healthcare costs and a rapid time to market. For more information, visit the Company's website at www.atlanticpharma.com.

Contact

Anthony Soscia

Phone: 678.638.6170

Atlantic Pharmaceuticals, Inc.

info@atlanticpharma.com